Argo Biopharma
Novartis Deepens RNAi Partnership with Argo Biopharma in $5.36B Cardiovascular Deal
Argo Biopharma and Novartis struck their third RNAi deal, focused on cardiovascular assets. With $160M upfront and $5.36B milestone potential, the collaboration spans ANGPTL3, dyslipidemia siRNAs, and IND-ready hepatic candidates.